Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6218755 | 0.89 | ADORA1 (0.49) | ADORA1ATMGPR119GLASMN1; SMN2 | |
| SCHEMBL12931062 | 0.88 | ADORA1 (0.53) | ADORA1GPR119GLASMN1; SMN2NPSR1 | |
| SCHEMBL26134595 | 0.86 | CHRM3 (0.48) | GPR119SMN1; SMN2MEN1ALDH1A1LMNA | |
| SCHEMBL6541860 | 0.82 | ADORA1 (0.47) | ADORA1ATMGPR119GLASMN1; SMN2 | |
| SCHEMBL31195159 | 0.80 | ADORA1 (0.48) | ADORA1ATMGPR119GLASMN1; SMN2 | |
| SCHEMBL15894090 | 0.80 | USP2 (0.47) | GPR119SMN1; SMN2MEN1ALDH1A1LMNA | |
| SCHEMBL13496714 | 0.79 | USP2 (0.46) | ATMGPR119SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL6958805 | 0.78 | ADORA1 (0.48) | ADORA1ATMGPR119GLASMN1; SMN2 | |
| SCHEMBL2081926 | 0.78 | ADORA1 (0.51) | ADORA1ATMGPR119SMN1; SMN2NPSR1 | |
| SCHEMBL12923869 | 0.78 | ADORA1 (0.51) | ADORA1ATMGPR119SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223277-A1 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS PHARMA AG (CH) | 2025-07-10 | — | — | US | disclosed |
| CN-119137099-A | Complement factor B inhibitors and uses thereof | 诺华股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2023187715-A1 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-10-05 | — | — | WO | disclosed |
| US-11584765-B2 | Polycyclic amines as sigma receptor modulators | Ecstasy LLC (US) | 2023-02-21 | — | — | US | disclosed |
| CN-110662541-B | Polycyclic amines as opioid receptor modulators | 王晓冬 | 2023-02-10 | — | — | CN | disclosed |
| US-20220411442-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | Ecstasy LLC | 2022-12-29 | — | — | US | disclosed |
| EP-3398598-B1 | SULFONAMIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | HITGEN INC (CN) | 2022-04-06 | — | — | EP | disclosed |
| US-11149008-B2 | Sulfamide derivatives and preparation method and use thereof | HitGen, Inc. | 2021-10-19 | — | — | US | disclosed |
| CN-106928198-B | Sulfonamide derivative and preparation method and application thereof | 成都先导药物开发股份有限公司 | 2020-07-28 | — | — | CN | disclosed |
| US-10676456-B2 | Polycyclic amines as opioid receptor modulators | Ecstasy LLC | 2020-06-09 | — | — | US | disclosed |
| EP-2420234-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION AS PARP INHIBITORS FOR USE IN TREATING CANCER | ABBOTT LAB (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2420499-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION AS POTENT PARP INHIBITORS | ABBOTT LAB (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2013025425-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-21 | — | — | WO | disclosed |
| EP-1869011-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LAB (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2420234-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as PARP inhibitors for use in treating cancer | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2420499-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as potent PARP inhibitors | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7550603-B2 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBOTT LABORATORIES INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1869011-A2 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006110816-A2 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676456-B2 | Polycyclic amines as opioid receptor modulators | OPRM1, OPRL1, OPRK1 | ADORA1 144/4885ATM 4130/4885GPR119 354/4885 |
| US-11584765-B2 | Polycyclic amines as sigma receptor modulators | OPRM1, SIGMAR1, OPRK1 | ADORA1 77/4885ATM 4020/4885GPR119 385/4885 |
| US-20250223277-A1 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | CFB, CFH, C1QBP | ADORA1 3280/4885ATM 3156/4885GPR119 2495/4885 |
| US-11149008-B2 | Sulfamide derivatives and preparation method and use thereof | HDAC6, HDAC1, HDAC11 | ADORA1 4138/4885ATM 3952/4885GPR119 762/4885 |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | PARP1, PARP2, PARP4 | ADORA1 3607/4885ATM 531/4885GPR119 3493/4885 |
| US-20220411442-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRK1 | ADORA1 144/4885ATM 4130/4885GPR119 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.